17,261 trials
Generalized Pustular Psoriasis
Primary: Time to First Generalized Pustular Psoriasis (GPP) Flare — 37.3; NA; NA; NA weeks — p=0.002
Nonalcoholic Steatohepatitis (NASH)
Primary: Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo. — -7.68; -9.17; -1.54 Percentage of liver fat…
Graft vs Host Disease
Primary: Phase I: MTD (USP hCG) — 2000; 2000; 5000 Pregnyl dosage (USP hCG)
Beta-Thalassemia · Non-transfusion-dependent Thalassemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 7; 3 Participants
Smith-Lemli-Opitz Syndrome
Primary: Change in Plasma Cholesterol — 37.8 change (%) compared to baseline — p=0.011
Covid-19
Primary: Recover Ratio — 47; 48; 1; 0 Participants
Familial Partial Lipodystrophy
Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides
Ebola Virus Disease
Primary: Number of Participants With Solicited Local (at the Administration Site) Adverse Events — 18 Participants
Transfusion Dependent Beta-thalassemia
Primary: Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion — 5; 2 participants
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
Breast Carcinoma · Estrogen Receptor Positive
Primary: Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI — 4; 1 Participants
Bone and Joint Infection
Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants
Alcohol Use Disorder · Bipolar Disorder
Primary: Prefrontal GABA+ Concentrations — 3.90; 3.93; 3.73 mmol/kg
Carcinoma, Non-Small-Cell Lung
Primary: Number of Subjects With Major Pathologic Response (MPR) — 17 Participants
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants